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Abstract
Background: Efficacy research has shown that intensive individual lifestyle intervention lowers the
risk for developing type 2 diabetes mellitus and the metabolic syndrome. Translational research is
needed to test real-world models of lifestyle interventions in primary care settings.
Design: E-LITE is a three-arm randomized controlled clinical trial aimed at testing the feasibility
and potential effectiveness of two lifestyle interventions: information technology-assisted self-
management, either alone or in combination with care management by a dietitian and exercise
counselor, in comparison to usual care. Overweight or obese adults with pre-diabetes and/or
metabolic syndrome (n = 240) recruited from a community-based primary care clinic are randomly
assigned to one of three treatment conditions. Treatment will last 15 months and involves a three-
month intensive treatment phase followed by a 12-month maintenance phase. Follow-up
assessment occurs at three, six, and 15 months. The primary outcome is change in body mass
index. The target sample size will provide 80% power for detecting a net difference of half a
standard deviation in body mass index at 15 months between either of the self-management or care
management interventions and usual care at a two-sided α level of 0.05, assuming up to a 20% rate
of loss to 15-month follow-up.
Secondary outcomes include glycemic control, additional cardiovascular risk factors, and health-
related quality of life. Potential mediators (e.g., treatment adherence, caloric intake, physical activity
level) and moderators (e.g., age, gender, race/ethnicity, baseline mental status) of the intervention's
effect on weight change also will be examined.
Discussion: This study will provide objective evidence on the extent of reductions in body mass
index and related cardiometabolic risk factors from two lifestyle intervention programs of varying
intensity that could be implemented as part of routine health care.
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Background
Diabetes mellitus affects nearly 24 million Americans (8%
of the U.S. population), and type 2 diabetes accounts for
about 90% to 95% of all diagnosed cases of diabetes [1,2].
The prevalence of diagnosed type 2 diabetes increased six-
fold in the latter half of the past century [1,2]. This dra-
matic increase is largely attributed to the epidemics of
obesity and physical inactivity [3]. About two-thirds of
U.S. adults are overweight or obese [4], and 57 million
people are estimated to have pre-diabetes -- a condition
characterized by blood glucose levels that are higher than
normal but not yet high enough to be diagnosed as diabe-
tes. Overweight or obese individuals with pre-diabetes are
at high risk for progression to diabetes. A vast majority of
these individuals also have an increased risk of cardiovas-
cular disease (CVD) because of concomitant risk factors,
such as abdominal obesity, atherogenic dyslipidemia, and
elevated blood pressure. The constellation of these com-
mon CVD risk factors is known as the metabolic syn-
drome [5].
The Diabetes Prevention Program (DPP) has demon-
strated that an intensive lifestyle intervention focused on
lifestyle changes and weight reduction can successfully
prevent or delay the onset of type 2 diabetes and the met-
abolic syndrome in overweight or obese adults with pre-
diabetes [6]. The DPP intervention required frequent,
face-to-face, individual counseling [7]. Despite evidence
of potential cost-effectiveness of the DPP intervention
[8,9], the substantial resources required for its implemen-
tation are a significant barrier to widespread dissemina-
tion. A wide range of research has been underway related
to translation of the DPP into real world settings, such as
studies that assess cost-effective and generalizable meth-
ods of delivering evidence-based lifestyle modifications in
small groups and over the Internet, as well as methods to
sustain behavior change and weight loss [10-12].
Recently, the 16 "core curriculum" individual counseling
sessions of the DPP intervention have been adapted for
delivery in a 12 session group-based program called
Group Lifestyle Balance (GLB)™ [13], and preliminary
evaluations of the program have suggested potential effec-
tiveness [14,15]. Past studies have shown that group inter-
ventions are similar in efficacy to individual interventions
for weight loss [16,17] and may markedly improve inter-
vention cost-effectiveness [8,9]. The Internet is another
alternative mode of delivery of lifestyle interventions. Sev-
eral randomized controlled trials have demonstrated the
efficacy of Internet-based lifestyle interventions in over-
weight or obese individuals [18-20], including those at
risk for type 2 diabetes [21].
To date, few studies have rigorously tested the feasibility
and effectiveness of group- and Internet-based lifestyle
interventions for weight management and risk reduction
in primary care settings. Weight loss in overweight or
obese patients with associated risk factors is of high prior-
ity for clinical care settings given the growing prevalence
of obesity-related complications, and preventative health
care is a major primary care goal. However, obesity and
risk factor management has thus far been largely a failure
in primary care settings throughout the United States
[22,23]. Research is needed to translate efficacious life-
style interventions into primary care practice, and in the
process, evaluate their cost-effectiveness, generalizability,
and sustainability.
Aims
The present study aims to evaluate the feasibility and
potential effectiveness of two lifestyle interventions, infor-
mation technology-assisted self-management alone (the
SM intervention) or SM combined with care management
by a dietitian and exercise counselor (the CM interven-
tion), in comparison to usual care (UC). The primary
hypothesis for each intervention (SM and CM) is that
intervention participants will achieve greater reductions
in body mass index (BMI) than UC participants at 15
months. Secondary research goals include comparing the
effects of each intervention to UC on changes in glycemic
control (fasting blood glucose and hemoglobin A1c),
additional cardiovascular risk factors (serum lipids, blood
pressure, waist circumference, and C-reactive protein
[CRP]), health-related quality of life and psychosocial
well-being. Differences between CM and SM intervention
effects on weight loss and secondary outcomes also will be
examined. Potential mediators (e.g., treatment adherence,
caloric intake, physical activity level) and moderators
(e.g., age, gender, race/ethnicity, baseline mental status)
of the intervention effects on weight change and second-
ary outcomes will be explored. Additionally, process
measures will be evaluated to assess the extent of partici-
pation of patients in each intervention and the potential
reach, adoption, implementation and maintenance of the
interventions in primary care practice.
Methods/Design
Study Design
E-LITE is a randomized controlled clinical trial in which
overweight or obese adults with an increased risk for CVD
and diabetes are equally randomized to one of three arms:
UC (control), SM, or CM. All procedures and materials
were approved by the Palo Alto Medical Foundation
Research Institute's Institutional Review Board.
Eligibility Criteria
Participants are recruited from a primary care health
center of the Palo Alto Medical Foundation (PAMF), a
community-based multi-specialty group practice in Cali-
fornia. Primary care patients ages 18 years and older whoBMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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are overweight or obese and have pre-diabetes and/or
metabolic syndrome are eligible to participate. Exclusion
criteria are designed to: 1) avoid potential contamination
and minimize confounding; 2) minimize safety concerns;
and 3) prevent poor adherence and loss to follow-up.
Table 1 enumerates the inclusion and exclusion criteria.
Recruitment and Screening Process
Target sample size for E-LITE is 240, recruited in three
sequential cohorts. The screening process for each cohort
begins with identification using relevant data available in
the patient's electronic health record of age-appropriate,
potentially eligible patients whose primary care provider
(PCP) regards the interventions under study to be medi-
cally appropriate and safe for that patient. Patients whose
participation is approved by their PCP are asked to com-
plete a brief questionnaire regarding major exclusions,
either online or by phone. Those who pass the initial
screen are scheduled for a formal eligibility determination
(baseline) visit (BV1), and, within two weeks prior to the
visit, they are contacted and given instructions for com-
pletion of an online baseline questionnaire.
Table 1: Participant inclusion and exclusion criteria
Inclusion criteria
1. Ethnicity: All ethnic groups;
2. Gender: Men and Women;
3. Age (as of date of enrollment):
a). Lower age limit: 18 years;
b). Upper age limit: NONE (only exclude for cause, e.g. diseases, functional limitations detailed below);
4. Body mass index ≥ 25.0 kg/m2;
5.Having pre-diabetes and/or metabolic syndrome based on the following criteria:
a). Pre-diabetes: fasting plasma glucose between 100 and 125 mg/dL;
b). Metabolic syndrome: Three or more of the following:
--Waist circumference ≥ 40 inches in men; ≥ 35 inches in women (if in Asian American ≥ 35 inches in men; ≥ 31 inches in women);
--Triglycerides ≥ 150 mg/dL;
--High-density lipoprotein cholesterol (HDL-C) < 40 mg/dL in men; < 50 mg/dL in women;
--Systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg;
--Fasting plasma glucose between 100 and 125 mg/dL.
6. Having a primary care physician (PCP);
7. Able and willing to enroll and provide written, informed consent, i.e., to: 1) meet the time and data collection requirements of the study; 2) be 
randomized to one of the three intervention arms; 3) adhere to the recommendations of the study intervention as assigned; 4) participate in 
follow-up for 12 months; and 5) allow extraction of relevant information from their medical records.
Exclusion criteria
1. Inability to speak, read or understand English;
2. No regular access to a computer with Internet and email capabilities;
3. Triglycerides ≥ 400 mg/dL;
4. Systolic blood pressure ≥ 160 mm Hg or diastolic blood pressure ≥ 100 mm Hg;
5. Initiation or change of drug therapy for elevated blood pressure or abnormal lipid levels within the past 3 months;
6. Initiation or change of antidepressant medication within the past 3 months;
7. Having a medical or physical condition that make moderate intensity physical activity (like a brisk walk) difficult or unsafe;
8. Use of weight-loss medications in the past 3 months;
9. Regular use (> 5 days/month) of medications that affect appetite or weight (e.g., oral corticosteroids, insulin, oral hypoglycemics etc.);
10. Currently enrolled in a lifestyle intervention program at PAMF or elsewhere;
11. Planning to undergo bariatric surgery during the study period;
12. Diagnosis of Type 1 or Type 2 diabetes mellitus;
13. Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), heart disease, stroke, and ongoing 
substance abuse;
14. Renal insufficiency (i.e. glomerular filtration rate < 60 mL/min/1.73 m2)
15. Diagnosis of psychiatric disorders that would limit adequate informed consent or ability to comply with study protocol;
16. Diagnosis of cancer (other than non-melanoma skin cancer) that was active or treated with radiation or chemotherapy within the past 2 
years;
17. Diagnosis of a terminal illness and/or in hospice care;
18. Pregnant, lactating or planning to become pregnant during the study period;
19. Already enrolled or planning to enroll in a research study that would limit full participation in this study or confound the observation and 
interpretation of the study's findings;
20. Family/household member of another study participant or of a study staff member;
21. No longer a PAMF patient or planning to transfer care outside of PAMF during the study period;
22. Planning to move out of the area during the study period;
23. PCP determination that the study is medically inappropriate or unsafe for the patient;
24. Investigator discretion for clinical safety or protocol adherence reasons.BMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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The BV1 occurs no more than four months after the initial
screen and no more than four weeks prior to randomiza-
tion. It includes completion of additional eligibility ques-
tionnaires, measurement of height, weight, waist
circumference, and resting blood pressure, and a fasting
blood draw for tests of plasma glucose and lipids at the
onsite Clinical Laboratory. Time permitting, a seven-day
physical activity recall [24] is completed; otherwise, it will
be completed at the baseline assessment/randomization
visit (BV2). Participants are given instructions and a three-
day food record form to be completed and returned at
BV2. Participants who have possible angina or peripheral
vascular disease based on the Rose Questionnaire [25] are
referred to their PCP for further evaluation and may only
continue with explicit authorization of their physician.
Participants who are eligible to continue on the basis of
BV1 are scheduled for BV2, which occurs at least seven
days after BV1 and no more than three weeks prior to the
start of the intervention. The BV2 includes measurement
of weight, waist circumference, and resting blood pres-
sure, a review of the three-day food record for complete-
ness, complete review of medication and supplement use,
a non-fasting blood draw for tests of A1c and CRP, and if
necessary, completion of the physical activity recall. Fol-
lowing the measurements, participants are randomized.
All participants are properly and adequately informed and
give appropriate consent at each step in the screening
process of the trial and prior to participating in the post-
randomization phase.
Randomization and Blinding
Participants are randomized on a 1:1:1 basis to one of
three arms: UC, SM, or CM. Pocock's "minimization" pro-
cedure [26] is used to assure better than chance group bal-
ance with respect to participant age, gender, race, BMI,
fasting blood glucose, waist circumference, and use of
PAMFOnline, which is PAMF's online patient portal to
access his or her own health record (user vs. non-user).
For each participant about to be randomized, a computer-
ized randomization algorithm automatically calculates an
imbalance score for each of the balancing factors, as the
excess or deficit of previously randomized participants in
each arm matching the current patient on that factor.
These scores are summed over factors to form a total
imbalance score, S, for each treatment arm. The randomi-
zation probability of assigning the patient to the treat-
ment associated with the smallest S is set to 2/3, and the
other two treatments are each assigned a probability of 1/
6 based on Efron's biased coin method [27].
A designated research staff member who is not involved in
follow-up data collection or data analysis assigns each
study arm a non-revealing label, e.g., A, B, or C, and per-
forms actual randomization of the participants. These
labels are used in all study documents and other materials
to ensure blinding of the investigators and staff responsi-
ble for follow-up data collection and analysis to partici-
pant treatment assignments throughout the trial.
Baseline and Follow-up Measures and Data Collection
Table 2 shows a complete list of study measures and the
data collection schedule. The time commitment of partic-
ipants is approximately 2 hours 45 minutes at baseline
(for completing the initial screen, baseline questionnaire,
BV1 and BV2), 45 minutes for the 3-month assessment,
and 1 hour 30 minutes each for the 6-month and 15-
month assessments.
Primary and Secondary Outcomes
The primary outcome measure is the BMI. Height and
weight, in light indoor clothes without shoes, are meas-
ured using a wall-mounted stadiometer and a balance
beam scale, respectively. All scales are calibrated quarterly
by trained study personnel using standard weights. BMI is
calculated as the Quetelet index (kg/m2).
Secondary outcomes include glycemic control and com-
ponent risk factors of the metabolic syndrome. Plasma
glucose, total cholesterol, triglycerides, and high-density
lipoprotein cholesterol (HDL-C) are measured after an
overnight fast, and low-density lipoprotein cholesterol
(LDL-C) is calculated by the Friedewald equation [28].
Hemoglobin A1c and CRP are also measured. Waist cir-
cumference is measured using a tape, according to a stand-
ardized protocol, in a horizontal plane around the
abdomen at the level of the right iliac crest[29] Blood
pressure is measured in the seated position after at least a
five-minute rest. At the BV1, blood pressure is measured
in both arms and the arm with the higher pressure is used
for all subsequent blood pressure measurements. At each
assessment visit, three blood pressure measurements are
obtained with one-minute between measurements, using
equipment and procedures that meet the American Heart
Association's recommendations for blood pressure meas-
urement in humans [30].
Additional secondary outcomes include generic and obes-
ity-specific health-related quality of life and mental
health. The 12-item Short Form Health Survey (SF-12)
[31], a widely used quality of life instrument, is adminis-
tered to evaluate changes in non-disease specific physical
and mental health status. The Obesity-Related Problem
Scale specifically measures the impact of obesity on psy-
chosocial functioning. The eight-item scale has high inter-
nal reliability and sound test--retest reliability, correlates
strongly with a wide range of theoretically related con-
structs, and is responsive to weight loss intervention [32].
The nine-item Patient Health Questionnaire (PHQ-9)BMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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refers to the previous two-week interval and consists of
nine items of depression symptoms and one follow-up
question on functional impairment [33]. The PHQ-9 is
both a measure of depressive symptomatology and a ten-
tative diagnostic instrument for the Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th  edition (DSM-IV)
depressive disorders [34]. The 21-item Depression Anxiety
Stress Scale has high internal consistency and correlates
strongly with other validated self-report measures of
depression, anxiety, and stress [35].
Furthermore, changes in diagnoses, medication use and
health care utilization will be assessed. With participant
authorization, data are extracted from their EHRs at base-
line and again at 15 months on current medical problems,
current prescription medications, and health care contacts
during the study (including outpatient visits, ER visits,
hospitalizations, and phone/email consultations). Phar-
macy dispensing data are currently available for patients
with capitated insurance only (making up about 30% of
the PAMF patient population). While the vast majority of
health care of PAMF primary care patients, including spe-
cialist care, is received from PAMF, a significant propor-
tion of medications prescribed are not obtained from the
PAMF pharmacy. Also, PAMF patients may seek care out-
side the system. Therefore, additional data are obtained
on medication and supplement use by recording informa-
tion from the container and on health care outside PAMF
by participant self-report.
Potential Mediators
Data are also obtained on a battery of behavioral and psy-
chosocial measures using existing self-report instruments
to assess potential mediators of the interventions.
The two main foci of the SM and CM interventions are
dietary changes to achieve weight loss and increased phys-
ical activity. Adherence to the interventions is assessed by
Table 2: List of measures and data collection schedule
Follow-up Month
Baseline 3 6 15
Clinical Measures
Height X
Weight XX X X
Waist circumference XX X X
Blood pressure XX X X
Fasting blood: Total cholesterol, LDL-C, HDL-C, triglycerides, glucose, hemoglobin A1c X X X
C-reactive protein (CRP) XX
Questionnaires
Demographics X
Family medical history X
Three-day food record XX X X
Eating Habits Confidence Survey XX X X
Social Support and Eating Habits Survey X X X X
Stanford Seven-day Physical Activity Recall X X X X
Exercise Confidence Survey XX X X
Social Support and Exercise Survey X X X X
Smoking and alcohol consumption XX
12-item Short Form Health Survey (SF-12) X X X X
Obesity Related Problems Scale XX X X
Nine-item Patient Health Questionnaire (PHQ-9) X X X X
Depression Anxiety Stress Scale XX X X
Symptoms XX X X
Adverse events XX X
Medication use XX X X
Care at non-PAMF health care facilities X X X X
Unified Theory of Acceptance and Use of Technology1 XX X
Data extracted from PAMF electronic databases
Current medical problems XX
Medications prescribed XX
Health care utilization XX
PCP characteristics X
1Questionnaire administered to participants in the SM and CM interventions only
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCP, primary care provider.BMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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three-day food records and the Stanford 7-Day Physical
Activity Recall. Multiple-day food records are considered a
gold standard for collection of individual dietary data
[36]. The Stanford 7-Day Physical Activity Recall has been
tested for validity and reliability [24] and is sensitive to
change in physical activity [37,38]. In addition, adherence
to the overall intervention "process" is assessed by docu-
menting attendance at group sessions, completion of self-
monitoring records, and frequency of use of the online
self-management support systems included in the SM and
CM interventions. Self-monitoring data obtained during
the intervention program also are used for adherence
monitoring and for individual feedback.
Based on the social cognitive theoretical underpinnings of
the intervention (see below), two main hypothesized
mediators of the intervention are selected to be measured:
self-efficacy and social support. The Eating Habits Confi-
dence Survey and the Exercise Confidence Survey [39],
and the Social Support and Eating Habits Survey and the
Social Support and Exercise Survey [40], have been shown
to be reliable and have high internal consistency and are
associated with other measures of social support and self-
efficacy related to physical activity and dietary behaviors.
The questionnaire created by Venkatesh et al. [41] based
on the Unified Theory of Acceptance and Use of Technol-
ogy, a technology acceptance model, is adapted to assess
user acceptance and use of the online self-management
support systems among SM and CM intervention partici-
pants. The questionnaire includes the following scales:
Performance Expectancy, Effort Expectancy, Social Influ-
ence, Facilitating Conditions, Attitude toward use, Self-
Efficacy, Anxiety and Behavioral Intention.
Additional Process Measures
Data on the proportion and representativeness of patients
willing to participate, as well as reasons for declining to
participate, are used to assess the potential reach of the E-
LITE interventions. Demographic and professional char-
acteristics of PCPs (e.g., age, sex, years in practice, spe-
cialty and board certification, PAMF department, panel
size and composition, %FTE) are obtained from PAMF
administrative records. Data on the proportion and repre-
sentativeness of physicians willing to approve their poten-
tially eligible patients for participation are used to assess
the likelihood of adoption of the E-LITE interventions.
Interventions
Theoretical Basis
The theoretical underpinning of the E-LITE interventions
is derived from Social Cognitive Theory [42] and the Tran-
stheoretical Model of Behavior Change [43]. The former
emphasizes the reciprocal determinism between individ-
ual, environment, and behavior, whereas the latter recog-
nizes that behavior change is a dynamic process that
moves, at variable speed, through varying stages of readi-
ness to change. Behavior change is more likely with
increased behavior capability, and behavior capability is
strengthened through goal setting, skill building and self-
monitoring. Also important are confidence in one's ability
to perform a given behavior (self-efficacy) and expecta-
tion of favorable outcomes of the behavior (outcome
expectations). Behavioral strategies may vary by stage of
change (i.e., experiential processes during initial phases of
behavioral adoption and behavioral processes occurring
during action and maintenance phases) [43]. In addition,
the E-LITE interventions draw upon key research evidence
for the importance of self-management in chronic disease
management [44-46]. Successful self-management inter-
vention is driven by patient-defined problems and fosters
the mastery of skills in problem solving, action planning,
decision making, and support building through an itera-
tive process [46,47].
This theoretical basis distinguishes the E-LITE interven-
tions from the delivery of lifestyle modifications in the
usual primary care setting. Current practice routinely
involves physician advice, occasionally with referral to a
dietitian who takes a diet history and who then provides
standard educational materials and advice during a small
number of individual or group sessions, typically with lit-
tle or no follow-up. This standard clinical approach lacks
the theoretical basis and behavioral self-management
focus described above.
Evidence-based Intervention Goals
A goal-based approach is used in both SM and CM inter-
ventions, in which participants are given the same general
goals: 7% weight loss and 150 minutes of moderate phys-
ical activity per week. These goals are consistent with
those of the DPP [7]. Participants who wish to lose more
than 7% of their starting weight may be encouraged to do
so only insofar as the participant maintains a normal BMI
at or above 21 and the rate of weight loss does not exceed
three pounds per week. The physical activity goal is con-
sistent with the new Physical Activity Guidelines for
Americans [48], and is deemed safe and attainable for
most adults. Participants, especially those who are habit-
ually sedentary, are advised to gradually and steadily
increase their activity level and reach the goal within five
weeks of beginning activity, or as soon as possible there-
after. Regular physical activity recommendations for activ-
ities of moderate intensity other than brisk walking, as
well as strength and flexibility physical activities, are to be
tailored to participant situation [49,50]. After attaining
the minimum goal of 150 minutes a week, participants
who wish to be more active are encouraged to do so, as
tolerated. If participants reach the 150-minute goal but
are not achieving the weight goal, they are encouraged toBMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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further gradually increase their physical activity to 60 min-
utes/day of moderate physical activity [49,51,52]. Partici-
pants in both SM and CM interventions are strongly
encouraged to track their weight and physical activity
using the American Heart Association's online self-man-
agement portal at http://www.heart360.com.
Recommendations are also given for total fat reduction
(to 25% of calories from fat) and calorie balance and
restriction (with a goal of a 500- to 1000-calorie reduction
diet). As in the DPP [7], the calorie and fat goals are given
as a means to achieve and maintain the weight goal, rather
than as a goal in and of itself. Therefore, if a participant
consumes more than the assigned calorie or fat goal, but
is achieving the weight goal, there is no need to focus on
further reductions. Portion control, choices of low-energy
and nutrient-dense meals and snacks, healthy food prep-
aration techniques, and careful selection of restaurants,
including fast food, and the items offered are promoted as
strategies to gradually achieve the calorie and fat goals.
Participants also are recommended to (1) lower saturated
fat intake to < 10% of caloric intake, (2) lower cholesterol
intake to < 300 mg/day, (3) consume a high plant-based
diet that includes a variety of fruits and vegetables, whole
grains, and low-fat dairy products, and (4) reduce intake
of high glycemic index carbohydrates.
Intervention Format, Structure, and Content
Both SM and CM interventions last 15 months and
involve Intensive Treatment and Maintenance phases.
Intensive Treatment Phase
The Intensive Treatment of both interventions lasts three
months and is based on the GLB program [13]. There are
12 weekly sessions and each lasts 90-120 minutes. Each
session follows a similar structure and includes five curric-
ulum components: 1) measurement and recording of
weight, 2) review of self-monitoring records and progress,
3) identification of personal barriers to weight loss and
activity and potential solutions, 4) presentation of a new
content area, and 5) goal setting and action plans for next
week.
SM condition. After attending a single-session group ori-
entation, participants in the SM intervention are given the
GLB program on a DVD to follow at home, with access to
a study dietitian via secure online messaging for advice
and support. Secure messaging is integrated with the elec-
tronic health record and allows patients to communicate
confidentially with their provider online. The DVDs are
provided by the Diabetes Prevention Support Center at
the University of Pittsburgh Diabetes Institute. Partici-
pants are encouraged to message the dietitian comments
and questions as they are completing the DVD program.
The dietitian will answer secure messages from partici-
pants within 1-2 work days and provide general support
and encouragement.
CM condition. Participants in the CM intervention receive
the GLB program in 12 weekly group sessions led by a
study dietitian and exercise physiologist. Both interven-
tionists have training and experience in weight manage-
ment counseling, and the dietitian has completed the GLB
2-day training workshop offered by the University of Pitts-
burgh's Diabetes Prevention Support Center. The sessions
are conducted in a highly interactive fashion. The GLB
Manual of Operations is closely followed, except for the
addition of a food tasting activity as part of the check-in
process and a 30-minute physical activity demonstration
at the end of each session. The food tasting activities are
aimed at increasing participant experience with healthy
food choices, encouraging them to try new foods that they
might not normally try on their own, and stimulating a
social, fun and engaging environment. The physical activ-
ity demonstrations are aimed at increasing participant
awareness of physical activity intensity, experiencing vari-
ous moderate-intensity activities that are safe and that
they can easily incorporate into their daily lives, and
increasing participant confidence. E-LITE participants in
both CM and SM arms receive a pedometer in the initial
session (the group orientation for the SM arm), as
opposed to in session 10 as in the original GLB program
[13].
Maintenance Phase
Both SM and CM interventions use secure online messag-
ing as the primary mode of contact between participants
and the dietitian during the maintenance phase. The con-
tact time is likely to vary depending on individual needs
in either intervention arm. The exercise physiologist is
available to counsel the dietitian on issues related to phys-
ical activity but she will have no direct communication
with participants in this phase. Participants are instructed
to continue monitoring their weight, dietary intake, and
physical activity at least twice each week.
SM condition. SM participants receive an email reminder
every two weeks to continue self-monitoring. As in the
Intensive Treatment phase, they are encouraged to submit
comments and questions to the dietitian via secure mes-
saging. The dietitian will respond to participant inquiries
but will not initiate contact.
CM condition. In contrast, the dietitian provides active
follow-up and individualized counseling to participants
in the CM group via secure messaging on at least a
monthly basis. Based on participant progress, the dietitian
provides tailored feedback to reinforce progress, recom-
mend problem solving and relapse prevention strategies,
and encourage maintenance efforts. As the participant isBMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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successful or not in attaining his/her current goals,
changes to the individual action plan are recommended,
e.g., modifying goals, adding to them, or replacing them
with new goals. The objective of any changes to the action
plan is to keep the goals realistic yet challenging and to
accommodate preferences and periodic fluctuations in
motivation and schedule. Participants are encouraged to
practice subject-initiated relapse prevention strategies,
with feedback and support from the dietitian. Participants
who fail to complete their self-monitoring diaries as
scheduled are queried about their progress relative to their
weight loss and behavioral change goals and any barriers
they have encountered in attaining those goals. They are
strongly encouraged to monitor and continue with the
intervention. At the discretion of the dietitian, partici-
pants may be phoned or seen to address outstanding
issues related to poor understanding of and/or adherence
to the intervention protocol.
Participant Safety
PCP approval is required before potentially eligible
patients are contacted by the study. Participants are care-
fully screened and individuals for whom the interventions
would be medically inappropriate or unsafe are excluded.
During screening, women who are pregnant, lactating, or
planning to become pregnant during the study period are
excluded. If a participant becomes pregnant during the
study, she is excluded immediately from further participa-
tion in all study activities, and her PCP is immediately
notified. Participants who develop any other exclusionary
condition (e.g., diabetes) following randomization may
continue with the interventions and follow-up assess-
ments only after explicit approval of their PCP. Surveil-
lance for adverse events and relevant clinical events occurs
by questionnaire at regularly scheduled intervals. Positive
responses trigger an adverse event record, which is
reviewed by the study physician for seriousness, study
relatedness, and expectedness within 72 hours. Similar
information reported by participants at other times (e.g.,
during intervention encounters) is duly noted and fol-
lowed up with as needed to assure participant safety. Par-
ticipants will be referred to their PCP for a medical
evaluation and follow-up as needed or recommended by
the study physician.
Retention
Adherence and retention in E-LITE is fostered by: 1) selec-
tion/retention, training, and quality control of qualified
staff; 2) the relationship between staff and participants, 3)
willingness to accommodate participant schedules and
needs, and 4) resourcefulness and persistence of the staff.
A participant tracking database is used to assure that par-
ticipants are contacted on a timely basis to obtain study
data. The assessment staff will contact participants who
miss a follow-up assessment to try re-engaging the patient
in subsequent follow-ups. Ongoing monitoring of indices
of participation in intervention activities helps interven-
tionists identify participants who are having problems
with adherence to the intervention protocol and thus
qualify for recovery efforts. Such efforts can range from
brief telephone discussion to an individualized coun-
seling session with an interventionist in which the partic-
ipant who makes a decision to discontinue intervention
can review concerns regarding E-LITE, reasons for staying
in E-LITE, and decisions about remaining a participant.
Unless the participant declines, the interventionist will
continue to contact the participant on a progressively less
frequent schedule, starting monthly and decreasing to
semi-annually to remind her/him of the opportunity to
re-enter E-LITE and to maintain contact for possible
recruitment for the final assessment at the end of E-LITE.
Sample Size Considerations and Statistical Analysis
Sample Size
Given the target sample size of 240, we expect approxi-
mately 80% power for detecting a net difference of 1/2 of
a standard deviation (equivalent to a medium effect size
of 0.5) in BMI at 15 months between the SM intervention
and usual care (and similarly, between the CM interven-
tion and usual care) at a 2-sided α level of 0.05, assuming
up to a 20% rate of loss to follow-up. The effect size is esti-
mated based on a number of successful lifestyle weight
loss intervention studies [6,18-20]. The power estimate
was calculated based on a t-test using simplified assump-
tions. Note that the t-test calculation is conservative
because it does not account for variance reduction due to
adjustment for baseline variables, nor for the better than
chance comparability of the experimental groups. The pri-
mary comparisons of each intervention with usual care
will be conducted using two-sided procedures at the over-
all significant level of 0.05. Multiplicity adjustments are
not necessary because the primary interest is to estimate
separate treatment effects for a limited number (i.e., n = 2)
of key contrasts that pertain to different interventions
[53]. Therefore, p-values of each comparison will be com-
pared to type I error α = 0.05 for significance.
Data Analysis
The primary hypothesis compares BMI between each
intervention (SM and CM) and usual care at 15 months
using an intent-to-treat analysis. Linear mixed modeling,
using SAS PROC MIXED [54] will test time and group
interactions to asses whether within-subject change in
BMI differs by condition. This basic analytical strategy
also accounts for the nature of repeated measurements,
the blocked design by cohorts, and the clustering of
patients within physicians. The same analysis strategy is
appropriate for evaluating secondary aims where the
hypotheses are identical but with different outcome meas-BMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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ures (e.g., glycemic control, other component risk factors
of the metabolic syndrome, and psychosocial well-being).
The longitudinal effects of the interventions will be
assessed using the same model, except that the focus is
comparisons within intervention groups at different time
points. Analyses will also be conducted to examine
whether there is a dose-response relationship between
intervention adherence and outcome, where dose is
defined in terms of number of group sessions attended,
number of secure messages sent, number of self-monitor-
ing logs, average daily intakes of calories and fat, and aver-
age number of minutes of physical activity per week.
For participants with missing outcomes at the primary
(15-month) or secondary (3- and 6-month) assessment
point, we will conduct and report on sensitivity analyses
in which different imputation methods are used (e.g., the
baseline-observation-carried-forward method, the "hot
deck" procedure, and an appropriate multiple imputation
method [55,56].
We will use the MacArthur approach, which modified the
Baron & Kenny criteria, for defining moderators and
mediators in clinical research studies [57]. Let T be the
treatment, M be the potential moderator or mediator, and
O be the outcome. Association between T, M, and O is
examined using the following models:
M is a moderator of the effect of T on O if M precedes T, γ1
= 0, and β3 ≠ 0. M is a mediator of the effect of T on O if T
precedes M, γ1 ≠ 0, and either β2 ≠ 0 or β3 ≠ 0.
Data Management
All study data are entered into computerized data files uti-
lizing: 1) Microsoft Access for participant tracking and
intervention data entry, 2) Vovici's survey software
(Dulles, VA) for self-administered questionnaires and
entry of clinical measurements, 3) Food Processor, v8.7
(ESHA Research, Oregon) for nutrient analysis based on
three-day food records, and 4) a custom-designed web
application for seven-day physical activity recall data
entry. Research assistants (blinded to treatment assign-
ment) will review participant responses on questionnaires
with participants present, and skipped or incorrectly
addressed items will be brought to the participant to cor-
rect. All of the data entry systems employ automatic, real-
time range, logic, and missing value checks. Data sets will
be cleaned, verified and archived, and then read into SAS
(Enterprise Guide 4.1; SAS Institute, Cary, NC) data sets,
which also are archived. One official copy of all the study
data and a master data dictionary are maintained and
updated regularly by the study data analyst. All analytic
and tracking database files are stored in a secure network
drive with daily backups. One copy of the backups is
saved on-site and one off-site. Separate archival databases
are permanently maintained. The data files can be shared
by authorized study personnel both on-site and in remote
locations via a secure virtual private network. Multiple lev-
els of password protection are utilized to ensure data secu-
rity.
Treatment Fidelity
Intervention quality assurance procedures ensure that
project activities are standardized across the intervention-
ists and across the cohorts and that intervention process
data are collected accurately. To achieve this, standardized
protocols, procedures, and educational materials are pre-
pared, and staff are systematically trained in their use. Pro-
vider and auditor checklists are created to ensure that the
intervention protocols are followed and that treatment
objectives for each group session are met. Interventionists
complete a Provider Checklist after each session. A ran-
dom sample of 10% of group sessions will be observed
and rated by a qualified individual using the Auditor
Checklist. When a session is reviewed with less than 85%
of treatment-specific objectives met, the auditor will
inform the PI who will remediate interventionist training
as needed. This process continues through all treatment
waves so that interventionist drift can be swiftly and con-
sistently corrected.
Discussion
The U.S. health care system has evolved primarily to react
to acute episodes of patient illness, and it remains largely
so even though chronic disease that is largely preventable
through lifestyle and behavior change has increasingly
dominated patient demands and health care expenditures
since the middle of the last century [58]. The enormous
clinical consequences of obesity demand that our health
care system resolutely take on the mission of obesity and
risk factor management and integrate this task into rou-
tine clinical care. Obese patients with pre-diabetes and/or
metabolic syndrome are a critical group because of their
increased lifetime risk for diabetes and CVD and the
potential reversibility of their condition. Yet current sys-
tems of care often fail to intervene when prevention is still
possible, responding only after irreversible adverse events
have occurred [59]. The standard clinical approach of
delivering lifestyle modifications not only lacks in the fre-
quency and intensity of contact to effect much change but
is also missing a solid theoretical basis and behavioral
self-management focus.
Efficacy trials such as the DPP [6] have shown that inten-
sive individual lifestyle intervention results in significant
weight loss and reduces the risks of type 2 diabetes and the
M =+ + γγ ε 01 T (1)
O =+ + + + ββ β β ε 01 2 3 TMT M (2)BMC Family Practice 2009, 10:71 http://www.biomedcentral.com/1471-2296/10/71
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metabolic syndrome. For intensive lifestyle interventions
proven efficacious in the research setting to be successfully
translated into routine clinical use, however, alternative
mechanisms of delivery must be sought that are both scal-
able to the large, growing population of obese or over-
weight patients with additional risk factors and
sustainable to provide ongoing patient self-management
support and monitoring.
E-LITE is a randomized clinical trial aimed at rigorously
evaluating the feasibility and potential effectiveness of
translating two lifestyle interventions into ongoing care of
overweight or obese adults with pre-diabetes and/or met-
abolic syndrome in a primary care practice. Studies of
integrating the DPP lifestyle intervention to primary care
settings are limited and few have used a randomized
design [11,14,15]. In E-LITE, a DPP-based curriculum will
be delivered in a self-guided DVD or in small groups, plus
ongoing individual counseling via secure online messag-
ing. Self-guided educational materials, group counseling,
and secure messaging are modalities in use in contempo-
rary health care systems. In addition to utilizing these
potentially cost-effective means of delivering the interven-
tion, the E-LITE study is designed and implemented with
close attention to existing resources, skills, and barriers of
the clinical setting in order to enhance its generalizability
and sustainability. For example, we will recruit from an
actual patient population in the clinic. We use data
already available in the electronic health record to first
identify an enriched pool of potentially eligible patients
and then adopt a physician referral approach to promote
safety and to facilitate integration of the intervention with
primary care. Furthermore, we utilize well-trained non-
physician clinicians (e.g., registered dietitians) who are
already in the health care workforce to deliver the inter-
ventions, which will help address commonly cited barri-
ers to primary care-based lifestyle programs in terms of
physician time commitment and training. Finally, secure
messaging is integrated with the electronic health record
and all communications between the interventionist and
the patient are viewable by the patient's PCP, which
allows for integration of the intervention into ongoing
care. Also, if proven successful, secure messaging would
help address the need for ongoing, long-term support --
one of the greatest challenges of maintaining healthy life-
styles -- in primary care practice. With the advent of elec-
tronic health record systems and associated
communication modalities, such population-based life-
style interventions are a realistic possibility in the primary
care setting.
Results from the E-LITE study will provide objective evi-
dence on the extent of reductions in BMI and related car-
diometabolic risk factors from two comprehensive,
evidence-based lifestyle interventions of varying intensity
that could be implemented as part of routine health care.
We will also assess the potential reach, cost effectiveness,
adoption, implementation, and maintenance of the inter-
ventions.
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